Detalhe da pesquisa
1.
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.
N Engl J Med
; 390(6): 510-521, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324484
2.
Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study.
J Eur Acad Dermatol Venereol
; 37(10): 2098-2108, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37317022
3.
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
J Am Acad Dermatol
; 86(4): 827-834, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34798201
4.
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2.
J Drugs Dermatol
; 20(8): 855-860, 2021 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34397205
5.
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
J Am Acad Dermatol
; 82(4): 936-945, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31809827
6.
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
N Engl J Med
; 373(2): 136-44, 2015 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26154787
7.
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
Br J Dermatol
; 189(1): 132-134, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36944555
8.
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
J Drugs Dermatol
; 17(8): 826-832, 2018 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30124721
9.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
J Am Acad Dermatol
; 76(3): 405-417, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28057360
10.
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ann Rheum Dis
; 73(6): 990-9, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24482301
11.
Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).
J Drugs Dermatol
; 12(2): 166-74, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23377389
12.
Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
J Drugs Dermatol
; 11(8): 943-9, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22859239
13.
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.
J Dermatolog Treat
; 33(2): 848-856, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32660282
14.
Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
J Dermatolog Treat
; 32(5): 484-491, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31613178
15.
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Lancet
; 373(9664): 633-40, 2009 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-19217154
16.
Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.
Ann Rheum Dis
; 69(4): 718-22, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20237125
17.
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
Am J Clin Dermatol
; 20(1): 155-164, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30417277
18.
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
J Invest Dermatol
; 139(12): 2437-2446.e1, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31207232
19.
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
JAMA Dermatol
; 154(6): 676-683, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29799960
20.
Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis.
J Invest Dermatol
; 139(8): 1830-1834.e6, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30851300